Spruce Biosciences, INC Form 4 insider transactions

Director Daniel K. Spiegelman acquired 30,000 stock options in Spruce Biosciences, Inc. on May 22, 2024.

Camilla V. Simpson, a director of Spruce Biosciences, acquired stock options for 30,000 shares on May 22, 2024.

Director Bali Muralidhar acquired 30,000 stock options in Spruce Biosciences on May 22, 2024, at an exercise price of $0.7511.

Michael G. Grey, Executive Chairman of Spruce Biosciences, acquired 30,000 stock options on May 22, 2024, according to a Form 4 filing with the SEC.

Percival Barretto-Ko, a director of Spruce Biosciences, acquired stock options for 30,000 shares on May 22, 2024.

Director Aynechi Tiba of Spruce Biosciences acquired 30,000 stock options on May 22, 2024, at an exercise price of $0.7511.

Novo Holdings A/S, a 10% owner of Spruce Biosciences, Inc., sold 465,021 shares of common stock at an average price of $0.7547 on March 21, 2024.

Novo Holdings A/S, a 10% owner of Spruce Biosciences, Inc., has sold a significant portion of its holdings over three days in March 2024.

Novo Holdings A/S, a 10% owner of Spruce Biosciences, INC., sold 1,912,316 shares of common stock at an average price of $0.8884 on March 14, 2024.

Ralph William Charlton III, Chief Medical Officer of Spruce Biosciences, reports the acquisition of 106,400 Restricted Stock Units (RSUs) on March 14, 2024.

Samir M. Gharib, CFO of Spruce Biosciences, reports the acquisition of 154,000 Restricted Stock Units (RSUs) tied to clinical development milestones.

CEO of Spruce Biosciences, Javier B. Szwarcberg, reports acquisition of 358,800 Restricted Stock Units (RSUs) on March 14, 2024.